IRON - Disc Medicine Opco Inc Stock Price and Quote

IRON | Disc Medicine Opco Inc | [NASD]

Index	-	P/E	-	EPS (ttm)	-4.82	Insider Own	0.60%	Shs Outstand	18.95M	Perf Week	-3.76%
Market Cap	634.66M	Forward P/E	-	EPS next Y	-4.14	Insider Trans	-	Shs Float	16.37M	Perf Month	0.90%
Income	-54.40M	PEG	-	EPS next Q	-0.88	Inst Own	85.10%	Short Float / Ratio	1.86% / 2.76	Perf Quarter	33.37%
Sales	-	P/S	-	EPS this Y	84.90%	Inst Trans	5.25%	Short Interest	0.30M	Perf Half Y	92.49%
Book/sh	12.28	P/B	2.65	EPS next Y	-5.60%	ROA	-32.80%	Target Price	40.75	Perf Year	159.20%
Cash/sh	12.12	P/C	2.68	EPS next 5Y	-	ROE	-35.00%	52W Range	11.80 - 37.48	Perf YTD	63.55%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-13.21%	Beta	-
Dividend %	-	Quick Ratio	24.30	Sales past 5Y	-	Gross Margin	-	52W Low	175.68%	ATR	2.34
Employees	46	Current Ratio	24.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	56.22	Volatility	8.10% 7.49%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	65.90%	Profit Margin	-	Rel Volume	0.48	Prev Close	32.05
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 31 BMO	Payout	-	Avg Volume	110.53K	Price	32.53
Recom	1.60	SMA20	-0.51%	SMA50	18.41%	SMA200	57.80%	Volume	53,510	Change	1.50%

Date	Action	Analyst	Rating Change	Price Target Change
May-17-23	Initiated	Raymond James	Outperform	$50
Apr-28-23	Initiated	Cantor Fitzgerald	Overweight	$45
Apr-21-23	Initiated	Stifel	Buy	$37
Apr-20-23	Initiated	Morgan Stanley	Overweight	$37
Mar-23-23	Initiated	BMO Capital Markets	Outperform	$40
Feb-28-23	Initiated	SVB Securities	Outperform	$36

May-15-23 07:00AM	Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-11-23 10:15AM	Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress (GlobeNewswire)
May-10-23 10:23AM	Is a Surprise Coming for Disc Medicine (IRON) This Earnings Season? (Zacks) +5.24%
May-05-23 08:50AM	Disc Medicine, Inc. (IRON) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
May-04-23 12:00PM	Disc Medicine, Inc. (IRON) Is Up 4.40% in One Week: What You Should Know (Zacks)
05:00AM	Loading…
Apr-28-23 05:00AM	Zacks.com featured highlights Harrow Health and Disc Medicine Opco (Zacks)
Apr-27-23 08:05AM	2 Stocks in Focus as Analysts Initiate Coverage (Zacks)
Apr-21-23 08:30AM	Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) +11.57%
Apr-19-23 08:50AM	Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why (Zacks)
Apr-13-23 11:00AM	Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Mar-31-23 07:00AM	Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-30-23 07:05AM	Disc Medicine Opco Inc (NASDAQ:IRON) most popular amongst private equity firms who own 48% of the shares, institutions hold 21% (Simply Wall St.)
Mar-21-23 07:00AM	Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA) (GlobeNewswire)
Feb-16-23 08:00AM	Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia (GlobeNewswire)
Feb-14-23 06:30AM	Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs (GlobeNewswire)
04:00PM	Loading…
Feb-08-23 04:00PM	Disc Medicine to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-20-23 07:00AM	Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis (GlobeNewswire)

Disc Medicine Opco Inc, together with its subsidiaries, operates as a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company builds a portfolio of fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. It also develops bitopertin for the treatment of erythropoietic porphyrias, erythropoietic protoporphyria, and X-linked protoporphyria. In addition, the company develops DISC-0974 for the treatment of chronic kidney disease; MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders; and DISC-0998 for the treatment of anemia associated with inflammatory. The company is based in Watertown, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AI DMI LLC	10% Owner	Feb 15	Buy	23.00	434,783	10,000,009	3,141,759	Feb 17 04:42 PM
Ashiya Mona	Director	Feb 15	Buy	23.00	108,696	2,500,008	1,196,825	Feb 17 04:48 PM
ORBIMED ADVISORS LLC	Director	Feb 15	Buy	23.00	108,696	2,500,008	1,196,825	Feb 17 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience